Alexandra Dretler, MD
Infectious Disease · Decatur, GANPI 1811251762
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.6%), consulting fees and education — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 61.0% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2023 at $6,940 and has fallen 96.1% since, to $273 in 2025.
Across 213 payments — averaging $51.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$7K
- Gilead$819
- Merck$575
- Insmed, Inc.$269
- AbbVie$254
- Astellas Pharma US Inc$238
- plus $2K from 32 others
Across 106 payments — averaging $1841.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$99K
- GSK$80K
- AbbVie$16K
What the payments were for
- Consulting fees$5,20048%
- Travel & lodging$180%
- Food & beverage$5,41950%
- Education$2893%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 53 | $6,665 |
| Gilead | 28 | $819 |
| Merck | 25 | $575 |
| Insmed, Inc. | 7 | $269 |
| AbbVie | 9 | $254 |
| Astellas Pharma US Inc | 9 | $238 |
| Cumberland Pharmaceuticals, Inc. | 4 | $217 |
| Janssen Scientific Affairs, LLC | 2 | $212 |
| Johnson & Johnson | 13 | $176 |
| Kerecis Limited | 3 | $173 |
| Smith+Nephew | 8 | $147 |
| Melinta Therapeutics, LLC | 7 | $143 |
| La Jolla Pharmaceutical Company | 5 | $141 |
| Janssen Products, LP | 2 | $110 |
| Organogenesis Inc. | 4 | $88 |
| Theratechnologies Inc. | 4 | $80 |
| Aroa Biosurgery Incorporated | 3 | $80 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $65 |
| Amgen(2 entities) | 3 | $64 |
| Shionogi Inc | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Integra Lifesciences Corporation | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| CSL Behring | 1 | $28 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| EMD Serono, Inc. | 1 | $21 |
| Next Science LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Mimedx Group, Inc. | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| GSK | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Hydrofera LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Reprise Biomedical, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,926 in reported general payments places this provider in the 85th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 74 | $306,083 |
| CabenuvaCabotegravir/Rilpivirine | 19 | $123,589 |
| DovatoDolutegravir Sodium/Lamivudine | 35 | $104,886 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $93,162 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 23 | $89,208 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 15 | $61,052 |
| Daptomycin | 29 | $57,416 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $38,228 |
| PrezcobixDarunavir/Cobicistat | 14 | $34,321 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 11 | $5,024 |
| Tacrolimus | 11 | $3,791 |
| Cefepime Hcl | 14 | $3,671 |
| Meropenem | 11 | $3,387 |
| Doxycycline Monohydrate | 24 | $411 |
| Fluconazole | 20 | $300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $819 | $306,08374 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Triumeq | $6,665 | $289,52769 claims |
| Janssen Products, LPSymtuza | $110 | $93,16218 claims |
| PfizerOctagam | $17 | $38,22812 claims |
| Johnson & JohnsonPrezcobix | $176 | $34,32114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Decatur
- Anson WurapaDecatur$47K
- Robin DretlerDecatur$27K
- Rafael HarpazDecatur$8K
- David SwerdlowDecatur$8K
- Milton BodenDecatur$8K
- Vincent MarconiDecatur$6K
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.